Mussel Protein Used to Develop New Vaccine Technology

Scientists in South Korea have developed a new adhesive adjuvant protein-based nanoparticle vaccine technology that they believe may provide longer-lasting immunity with a single injection. According to the researchers in a study published in the journal Biomaterials in 2026, the new approach used bioengineering, gene synthesis and cloning to create a new vaccine technology using the natural adhesive properties of mussels to keep vaccine ingredients in the body for a longer period, giving the immune system more time to build an enhanced humoral and cell mediated immune response and longer protection.

The nanoparticle vaccine adheres to tissue and releases both antigens and adjuvants in the body over a sustained period of time. The research team says this slow-release technology could reduce the need for repeated booster shots and improve vaccine access in areas with limited health care resources.¹

Most vaccines, including influenza, pertussis and COVID-19 shots, do not provide long lasting immunity, which decreases over time, and multiple booster doses are given to try to extend immunity. The researchers who developed the mussel-based protein nanoparticle vaccine explained in their study that repeated booster shots increase health care costs, require additional clinic visits, and make vaccination programs more difficult in countries with limited medical infrastructure. These challenges prompted them to begin searching for a way to create a vaccine that would provide longer-lasting immunity with fewer injections.²

Researchers Turn to Mussels to Create a New Vaccine Platform

The scientists found that mussels produce a powerful natural adhesive protein that allows them to stick to rocks underwater. The researchers combined the mussel adhesive protein with an immune-boosting peptide called pan-HLA-DR-binding epitope (PADRE) to create an Adhesive Adjuvant Protein (AAP). According to the study, AAP forms tiny nanoparticles with vaccine antigens that remain at the injection site and release the vaccine gradually instead of breaking down quickly. The researchers believe this slow-release process helps sustain the inflammatory response to be more effective over time.³

According to the study’s findings, the AAP-based vaccine stayed in the body much longer than traditional vaccines that use aluminum-based adjuvants. The team reported that a single injection of the experimental mussel protein nanoparticle vaccine produced “potent immune responses” and protection lasting more than three times longer than conventional vaccine formulations. They believe the gradual release of vaccine components continuously stimulates immune responses that create a stronger and more durable immune protection.⁴

The researchers reported that the vaccine activated several important immune cells. According to the study, the PADRE peptide strengthened the MHC Class II immune pathway, increasing helper T cells that support antibody production and memory T cells that provide long-term protection. The team also observed greater activity in cytotoxic T-cells, which attack virus-infected and cancer cells. Researchers said they found no evidence of immune exhaustion and maintained that the immune system remained effective throughout the response.⁵

The vaccine developers acknowledge that more research is needed before the vaccine can be used in humans, but said they believe the new approach has promising applications beyond infectious diseases. Noting that the adhesive adjuvant protein-based nanoparticle technology can be used for large-scale production of product, the researchers want to adapt the same platform for therapeutic cancer vaccines, particularly for “cold tumors” (tumors that the immune system struggles to recognize and attack), which often respond poorly to current immunotherapy treatments.⁶

If you would like to receive an e-mail notice of the most recent articles published in The Vaccine Reaction each week, click here.